Table 3. Adverse drug reactions to first-line anti-tuberculosis drugs according to time-to-onset.
| Adverse drug reactions | < 1 mon | 1–2 mon | > 2 mon | Missing values | Total |
|---|---|---|---|---|---|
| Nausea | 2,108 (80.7) | 255 (9.8) | 186 (7.1) | 62 (2.4) | 2,611 |
| Rasha | 1,520 (72.8) | 266 (12.7) | 241 (11.5) | 62 (3.0) | 2,089 |
| Hepatic enzyme abnormalityb | 1,386 (54.8) | 654 (25.8) | 430 (17.0) | 61 (2.4) | 2,531 |
| Pruritis | 1,097 (67.8) | 253 (15.6) | 193 (11.9) | 74 (4.6) | 1,617 |
| Vomiting | 1,305 (82.2) | 151 (9.5) | 98 (6.2) | 33 (2.1) | 1,587 |
| Urticaria | 525 (70.9) | 108 (14.6) | 84 (11.4) | 23 (3.1) | 740 |
| Anorexia | 533 (77.0) | 101 (14.6) | 45 (6.5) | 13 (1.9) | 692 |
| Dyspepsia | 436 (70.0) | 103 (16.5) | 62 (10.0) | 22 (3.5) | 623 |
| Dizziness | 471 (80.2) | 52 (8.9) | 41 (7.0) | 23 (3.9) | 587 |
| Arthralgia | 333 (60.2) | 114 (20.6) | 80 (14.5) | 26 (4.7) | 553 |
| Diarrhea | 371 (78.1) | 35 (7.4) | 42 (8.8) | 27 (5.7) | 475 |
| Headache | 359 (78.4) | 45 (9.8) | 52 (11.4) | 2 (0.4) | 458 |
| Fever | 349 (89.9) | 25 (6.4) | 10 (2.6) | 4 (1.0) | 388 |
| Hyperuricemia | 251 (73.2) | 56 (16.3) | 30 (8.7) | 6 (1.8) | 343 |
| Myalgia | 175 (78.1) | 27 (12.1) | 15 (6.7) | 7 (3.1) | 224 |
| Abdominal pain | 175 (82.2) | 4 (1.9) | 25 (11.7) | 9 (4.2) | 213 |
| Malaise | 141 (87.6) | 9 (5.6) | 11 (6.8) | 0 (0) | 161 |
| Eosinophilia | 85 (62.5) | 29 (21.3) | 15 (11.0) | 7 (5.2) | 136 |
| Fatigue | 93 (74.4) | 24 (19.2) | 8 (6.4) | 0 (0) | 125 |
| Leukopenia | 54 (52.4) | 18 (17.5) | 22 (21.4) | 9 (8.7) | 103 |
| Dyspnea | 66 (71.0) | 16 (17.2) | 9 (9.7) | 2 (2.2) | 93 |
| Thrombocytopenia | 48 (58.5) | 13 (15.9) | 18 (22.0) | 3 (3.7) | 82 |
| Vision abnormality | 57 (73.1) | 11 (14.1) | 5 (6.4) | 5 (6.4) | 78 |
| Tremor | 49 (65.3) | 17 (22.7) | 9 (12.0) | 0 (0) | 75 |
| Cachexia | 51 (71.8) | 7 (9.9) | 9 (12.7) | 4 (5.6) | 71 |
| Constipation | 40 (63.5) | 15 (23.8) | 8 (12.7) | 0 (0) | 63 |
| Weight decrease | 32 (59.3) | 14 (25.9) | 8 (14.8) | 0 (0) | 54 |
| Neuropathy | 25 (58.1) | 4 (9.3) | 13 (30.2) | 1 (2.3) | 43 |
| Paresthesia | 20 (50.0) | 7 (17.5) | 12 (30.0) | 1 (2.5) | 40 |
| Chest pain | 25 (71.4) | 6 (17.1) | 4 (11.4) | 0 (0) | 35 |
| Acne | 5 (14.7) | 3 (8.8) | 26 (76.5) | 0 (0) | 34 |
| Edema | 13 (39.4) | 14 (42.4) | 6 (18.2) | 0 (0) | 33 |
| Facial edema | 18 (58.1) | 0 (0) | 5 (16.1) | 8 (25.8) | 31 |
| Insomnia | 12 (41.4) | 14 (48.3) | 1 (3.5) | 2 (6.9) | 29 |
| Gout | 16 (55.2) | 8 (27.6) | 1 (3.5) | 4 (13.8) | 29 |
| Coughing | 22 (78.6) | 4 (14.3) | 2 (7.1) | 0 (0) | 28 |
| Pancytopenia | 12 (42.9) | 7 (25.0) | 5 (17.9) | 4 (14.3) | 28 |
| Renal function decrease | 9 (32.1) | 11 (39.3) | 7 (25.0) | 1 (3.6) | 28 |
| Angioedema | 23 (85.2) | 0 (0) | 4 (14.8) | 0 (0) | 27 |
Data are shown as numbers (row %).
aRash includes ‘rash, rash maculopapular and rash erythematous’; bHepatic enzyme abnormality includes hepatic enzyme increased, hepatic function abnormal, SGOT increased, SGPT increased ‘jaundice, hepatitis, gamma-GT increased, bilirubinemia, hepatocellular damage, and cholecystitis’.